亚洲三级黄色,免费黄色大片网站,欧美一级在线免费,三级国产毛片,999精品在线播放,精品国产一区二区三区不卡蜜臂,在线97

I. Geographic Location

1. Registered Address: Room 1501, No. 2003 Qunxian Road, Keqiao District, Shaoxing City, Zhejiang Province

2. Production Site: No. 36 Nanbin West Road, Lihai Subdistrict, Yuecheng District, Shaoxing City, Zhejiang Province

II. Product Details

1. Core Products: Cefmetazole Sodium for Injection, Azithromycin for Injection, Omeprazole Sodium for Injection, Azithromycin Dispersible Tablets, Amoxicillin Clavulanate Potassium Dispersible Tablets, Spironolactone Tablets, Roxithromycin Capsules, Cefixime Capsules, Celecoxib Capsules, Mosapride Citrate Granules.

2. Business Segments: A national high-tech pharmaceutical enterprise integrating R&D, production, and sales. Product portfolio includes tablets, hard capsules, freeze-dried powder for injection, powder for injection, granules, transdermal patches, and other dosage forms, holding 114 drug approval numbers.

3. Distinctive Advantages: Comprehensive portfolio of antibiotics across multiple dosage forms, complemented by transdermal controlled-release systems, cardiovascular drugs, hypoglycemic agents, and hepatitis medications. Over 60 core products.

III. Enterprise Scale

1. Production Capacity/Facility Scale:

(1) Solid Dosage Form Workshop (Workshop 51): Annual production of 1.2 billion tablets;

(2) Solid Dosage Form Workshop (Workshop 52): Annual production of 1 billion capsules;

(3) Freeze-Dried Powder Injection Workshop (Workshop 53): Annual production of 58 million vials of freeze-dried powder injections;

(4) Cefalosporin Capsule Workshop (Workshop 61): Annual production of 500 million capsules;

(5) Penicillin Solid Dosage Form Workshop (Workshop 71): Annual production of 400 million capsules and 240 million tablets;

(6) Cefalosporin Powder for Injection Workshop (Workshop 72): Annual production of 50 million vials.

2. Number of Branches: Asia-Pacific Pharmaceuticals' products cover all provinces, municipalities, and autonomous regions in China, with over 50 branch offices established nationwide.

IV. Industry Position

The company ranks among the top in Zhejiang Province for the variety, production volume, and sales of antibiotic products.

V. R&D Capabilities

1. R&D Team Scale: The R&D center spans 6,400 square meters with 22 researchers, including 2 master's degree holders and 17 bachelor's degree holders.

2. Patent Portfolio: 21 invention patents and 14 utility model patents.

3. Industry-Academia-Research Collaboration: Collaborated with Zhejiang University on the CX3002 project, with Zhejiang Medical Academy on the dextroketorofen sustained-release patch project, and with Fudan University on the amoxicillin sustained-release tablet project. Future plans include collaborative development of complex dosage forms such as compound preparations.

VI. Future Plans (3-5 Year Strategic Goals)

1. Establish a Comprehensive Pharmaceutical Industry Chain Ecosystem

(1) Vertical Integration: Accelerate the integration of “raw materials-formulations-sales-services” through acquisitions of GSP-certified companies and sales reforms. Build an end-user channel network (covering hospitals/pharmacies/third-party terminals), secure scarce distribution licenses (including cold chain and specialty drug permits), and expand product portfolios to achieve the strategic objectives of “performance assurance + channel control + transformation planning.”

(2) High-End Capacity Development: Within 3 years, establish 1-2 dedicated production lines for high-value-added drugs (focusing on chiral compounds, controlled-release formulations, oral hormone solutions, etc.) to break free from the low-profit trap of traditional pharmaceuticals. Within 5 years, complete construction of GMP facilities compliant with dual China-US certification (China NMPA/US FDA) to support internationalization and innovative drug commercialization.

Through dual-track advancement in capacity upgrades and channel control, we will strengthen supply chain security, enhance capital premium potential, and establish long-term competitive moats amid the normalization of centralized procurement.

2. Establish a Modern R&D System Integrating Generic and Innovative Development

(1) Generic Drug R&D Upgrade: Focus on first-to-market generics, complex formulations (controlled-release, inhalation, liposomal, etc.), and high-barrier API development. Launch 5-8 high-margin products within 3 years; establish a fast-track for consistency evaluation to ensure existing products continuously meet centralized procurement quality standards. Establish a Class B licensed company in Binhai New Area as a new growth engine for the Asia-Pacific region, continuously increasing R&D investment proportion, and prioritizing the development of high-end formulation technology platforms.

(2) Innovative Drug Strategy: Establish a dedicated innovation incubation fund to advance 1-2 Class I new drugs into clinical trials within 5 years; develop improved new drugs with distinct clinical advantages through formulation innovation; introduce early-stage clinical projects via BD partnerships to establish a dual-engine model of “in-house R&D + licensed introductions.”

(3) Technology Platform Development: Complete construction of controlled-release technology platforms, biopharmaceutical R&D platforms (macromolecules/ADC), and AI-assisted drug design centers; apply for provincial-level key laboratories, doubling core patent holdings within three years.

Achieve deep synergy between R&D pipelines, API production capacity, and sales channels within five years to accelerate innovation commercialization, providing core product support for the Group's healthcare industry strategy.

3. Expand business scope through capital strength to establish a preliminary health platform

    The company plans to broaden its business scope via capital mergers and acquisitions within the next three years. It will focus on acquiring “small yet promising” targets in traditional Chinese medicine, medical equipment, and machinery sectors to enrich the Asia-Pacific health industry and lay a solid foundation for strengthening and expanding the Group's pharmaceutical platform.

VII. Key Honors and Awards